Royal Philips, a global leader in health technology, announced the introduction of the industry’s first full-service, at-home, 12-lead electrocardiogram (ECG) solution for use in decentralized ...
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, ...
HeartBeam has received FDA clearance for its synthesized 12-lead ECG software, making it the first cable-free device of its kind for at-home arrhythmia assessment. The clearance followed a successful ...
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that the U.S. Food and Drug ...
Twelve-lead ECGs, although standard in hospitals, can be bulky and impractical for home use. On the other hand, Apple Watch’s ECG app is easy to use, but it is limited in what it can detect because it ...
The company notes the synthesized output is not intended to replace a standard 12-lead ECG. HeartBeam also plans to advance development of an on-demand 12-lead ECG extended wear monitor and build ...
Department of Medical-Diagnostic Sciences, University of Padua, Padua, Italy Correspondence to Dr D Corrado, Department of Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, ...
Philips expands remote cardiac monitoring portfolio with patch-based, clinical-grade ECG designed to improve patient recruitment, compliance and retention by reducing need for site visits during ...
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results